Michael P Rettig
Overview
Explore the profile of Michael P Rettig including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
2272
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abboud R, Schroeder M, Rettig M, Jayasinghe R, Gao F, Eisele J, et al.
Blood
. 2024 Nov;
PMID: 39576962
Haploidentical hematopoietic cell transplantation (haplo-HCT) is an increasingly used treatment for hematologic malignancies. Although post-transplant cyclophosphamide (PtCy) has improved graft vs. host disease (GvHD) prophylaxis in haplo-HCT, patients continue to...
2.
Ruminski P, Rettig M, Dipersio J
Biomolecules
. 2024 Aug;
14(8).
PMID: 39199390
The treatment of patients diagnosed with hematologic malignancies typically includes hematopoietic stem cell transplantation (HSCT) as part of a therapeutic standard of care. The primary graft source of hematopoietic stem...
3.
Pilcher W, Yao L, Gonzalez-Kozlova E, Pita-Juarez Y, Karagkouni D, Acharya C, et al.
bioRxiv
. 2024 May;
PMID: 38798338
Multiple Myeloma (MM) remains incurable despite advances in treatment options. Although tumor subtypes and specific DNA abnormalities are linked to worse prognosis, the impact of immune dysfunction on disease emergence...
4.
Eissenberg L, Ritchey J, Rettig M, Patel D, Vij K, Gao F, et al.
PLoS One
. 2024 May;
19(5):e0300174.
PMID: 38696390
Off-the-shelf immunotherapeutics that suppress tumor growth and provide durable protection against relapse could enhance cancer treatment. We report preclinical studies on a CD33 x CD3 bivalent bispecific diabody, AMV564, that...
5.
Yelamali A, Chendamarai E, Ritchey J, Rettig M, Dipersio J, Persaud S
bioRxiv
. 2024 Feb;
PMID: 38405731
Hematopoietic stem cell transplantation (HSCT) conditioning using antibody-drug conjugates (ADC) is a promising alternative to conventional chemotherapy- and irradiation-based conditioning regimens. The drug payload bound to an ADC is a...
6.
Cancilla D, Rettig M, Karpova D, Thakellapalli H, Singh M, Meyers M, et al.
Blood Adv
. 2024 Jan;
8(6):1379-1383.
PMID: 38190608
No abstract available.
7.
Goldsmith S, Covut F, Fiala M, Xiang Z, Iqbal Z, Moore N, et al.
Open Forum Infect Dis
. 2023 Nov;
10(11):ofad518.
PMID: 37953814
Background: Despite improvements in prevention and treatment, severe coronavirus disease 2019 (COVID-19) is associated with high mortality. Phosphoinositide 3-kinase (PI3K) pathways contribute to cytokine and cell-mediated lung inflammation. We conducted...
8.
Ghobadi A, Foley N, Cohen J, Rettig M, Cashen A, Gehrs L, et al.
Blood Adv
. 2023 Oct;
8(3):513-522.
PMID: 37871306
Outcomes in patients with relapsed diffuse large B-cell lymphoma (DLBCL) who undergo autologous stem cell transplant (auto-SCT) are poor. Blinatumomab is a CD3/CD19 bispecific T-cell engager that directs cytotoxic T...
9.
Xiang J, Devenport J, Carter A, Staser K, Kim M, O Neal J, et al.
Leukemia
. 2023 Oct;
37(12):2448-2456.
PMID: 37798328
T-cell malignancies are associated with frequent relapse and high morbidity, which is partly due to the lack of effective or targeted treatment options. To broaden the use of CAR-T cells...
10.
Crees Z, Rettig M, Bashey A, Devine S, Jaglowski S, Wan F, et al.
Blood Adv
. 2023 Jun;
7(18):5210-5214.
PMID: 37327120
No abstract available.